OPEN LETTER

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions [version 2; peer review: 2 approved]

William HK Schilling1,2, James J. Callery1,2, Arjun Chandna1,3, Raph L Hamers1,4, James A Watson1,2, Nicholas J White1,2

1Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
2Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
3Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia
4Eijkman Oxford Clinical Research Unit, Eijkman Institute for Molecular Biology, Jakarta, Indonesia

Abstract

The World Health Organization (WHO) living guideline on drugs to prevent COVID-19 has recently advised that ongoing trials evaluating hydroxychloroquine in chemoprophylaxis should stop. The WHO guideline cites “high certainty” evidence from randomised controlled trials (RCTs) that hydroxychloroquine prophylaxis does not reduce mortality and does not reduce hospital admission, and “moderate certainty” evidence of poor tolerability because of a significantly increased rate of adverse events leading to drug discontinuation. Yet there is no such evidence. In the three pre-exposure chemoprophylaxis RCTs evaluated in the guideline there were no deaths and only two COVID-19-related hospital admissions, and there was a mistake in the analysis of the number of discontinuations (after correction there is no longer a statistically significant difference between those taking the drug and the controls). Guidelines on the prevention and treatment of COVID-19 should be based on sufficient verified evidence, understanding of the disease process, sound statistical analysis and interpretation, and an appreciation of global needs. The WHO living guideline on the prevention of COVID-19 should retract the advice to stop research on hydroxychloroquine chemoprophylaxis, should correct its errors, and should revise its guidance.

Keywords

SARS-CoV-2, COVID-19, Coronavirus, Prophylaxis, Pre-exposure, Guideline
This article is included in the **Mahidol Oxford Tropical Medicine Research Unit (MORU)** gateway.

This article is included in the **Coronavirus (COVID-19)** collection.

**Corresponding author:** William HK Schilling (william@tropmedres.ac)

**Author roles:**
- **Schilling WH**: Conceptualization, Funding Acquisition, Investigation, Writing – Review & Editing; **Callery JJ**: Conceptualization, Investigation, Writing – Review & Editing; **Chandna A**: Conceptualization, Investigation, Writing – Review & Editing; **Hamers RL**: Investigation, Writing – Review & Editing; **Watson JA**: Conceptualization, Formal Analysis, Investigation, Visualization, Writing – Review & Editing; **White NJ**: Conceptualization, Investigation, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** The authors are all investigators on the COPCOV study; Chloroquine/hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (ClinicalTrials.gov; https://clinicaltrials.gov/ct2/show/NCT04303507; 11/03/2021).

**Grant information:** Funding for the COPCOV study is from the UK Wellcome Trust [220777].

**Copyright:** © 2021 Schilling WH et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Schilling WH, Callery JJ, Chandna A et al. *The WHO guideline on drugs to prevent COVID-19: small numbers-big conclusions [version 2; peer review: 2 approved]* Wellcome Open Research 2021, 6:71 [https://doi.org/10.12688/wellcomeopenres.16741.2](https://doi.org/10.12688/wellcomeopenres.16741.2)

**First published:** 30 Mar 2021, 6:71 [https://doi.org/10.12688/wellcomeopenres.16741.1](https://doi.org/10.12688/wellcomeopenres.16741.1)
Introduction

World Health Organization (WHO) guidelines are generally held in high esteem because the judgements are usually based on solid and substantial evidence. However, on 2 March 2021 the WHO issued a guideline on COVID-19 chemoprophylaxis which included unusual and unjustified judgements with far reaching implications derived from small numbers of observations\(^1\). It also contained an important mistake. There are several analogies between the legal system and clinical investigations, and in particular the interpretation of clinical trials and the production of treatment guidelines. Both seek the truth, both review the strengths and weaknesses of evidence, and both end in a judgement. In clinical guidelines the judgement is based on an appraisal of risks and benefits. The WHO guideline uses standard methodological approaches to evaluate and grade clinical research outputs and to generate guidelines\(^1\). In general, this is a conservative process requiring a substantial quality evidence base for definitive recommendations. This reduces uncertainty in the assessments, and it helps ensure that the consequent guidelines are robust. We argue that this has not happened for the WHO guideline on drugs to prevent COVID-19.

The WHO ‘living’ guideline provides a strong recommendation against hydroxychloroquine in COVID-19 pre- or post-exposure prophylaxis\(^1,2\). In many ways, hydroxychloroquine has become the COVID-19 pariah, but it still deserves a fair trial. It is true that hydroxychloroquine for both treatment and prevention was intensely politicised, and it was recommended prematurely by many governments, institutions and prominent individuals early in the COVID-19 pandemic. It should not have been. It is also true that definitive large randomised controlled trials (RCTs) have shown unequivocally that hydroxychloroquine is not life-saving in hospitalised patients\(^4\). This is the stage of the disease when anti-inflammatory drugs, such as dexamethasone or interleukin 6 (IL-6) receptor antagonists, but not small molecule antiviral drugs (notably remdesivir), have proved lifesaving\(^5,6\). Unfortunately, in addition to extreme politicisation and extensive speculation, perceptions of risk from hydroxychloroquine were distorted, and ongoing trials were badly damaged by the Surgisphere\(^®\) fiasco in May 2020\(^7\). A very large multinational study, led by eminent cardiologists and published in The Lancet, claimed to show that hydroxychloroquine increased the risk of lethal ventricular arrhythmias. Some regulatory authorities stopped ongoing trials immediately. However, it rapidly became apparent that the Surgisphere\(^®\) data, upon which the study was based, contained implausible results, could not be accessed, and were likely fabricated. Although this paper, and another from the same team published earlier in the New England Journal of Medicine, were swiftly retracted\(^8\) the regulatory authorities were slow to reverse their positions, opinion swung against hydroxychloroquine despite the fraudulent report, and lasting damage was done.

It is accepted that antiviral drugs are more likely to have disease modifying efficacy early in the COVID-19 illness, whereas anti-inflammatory drugs have proven benefit later in severely ill patients. Extrapolating therapeutic results from severe disease to early illness or prevention is not justified\(^9,10\). However, in contrast to the large randomised controlled trials (RCTs) in hospitalised patients, relatively few patients have been enrolled in studies of hydroxychloroquine in early treatment, or in post-exposure (PEP) or pre-exposure prophylaxis (PrEP). In the three published, or posted, pre-exposure prophylaxis RCTs there were very few endpoints\(^1,2\). Nevertheless, the WHO guideline has concluded definitively, based upon the data from these trials, that hydroxychloroquine does not provide useful benefit in any of these situations. The WHO guideline group has also taken the unusual step of advising funders and researchers that they should reconsider the initiation and continuation of ongoing trials, i.e. they should stop. So, although it is described as a “living guideline”, without further evidence it is unlikely that this particular guideline would live much longer.

From a statistical perspective both the justice system, and the institutions which issue disease prevention and treatment regulatory approvals and guidelines, focus primarily on demonstrating proof beyond reasonable doubt. Trials that lead to conviction have proved guilt beyond reasonable doubt. Pre-registration RCTs aim to prove efficacy of a drug beyond reasonable doubt, in addition to showing that the cost of this efficacy is not too high in terms of tolerability and safety. In the WHO COVID-19 prophylaxis guideline the opposite is
being done. A definitive statement is made about lack of clinical utility. According to the guideline the highest efficacy estimate compatible with the data (lower end of the confidence interval) is not a clinically useful effect. Despite the small number of endpoints, and therefore large uncertainty, the guideline states firmly that hydroxychloroquine chemoprophylaxis results in no important differences in mortality, admission to hospital, or laboratory confirmed COVID-19. It also claims that adverse events (AEs) leading to drug discontinuation are a significant problem for hydroxychloroquine prophylaxis. Both contributed to the WHO judgement that hydroxychloroquine should not be used, and should not be evaluated further in COVID-19 prophylaxis trials.

Nearly all the evidence used to generate this strong recommendation was in the public domain for several months before the March WHO guideline was published. It comprises three RCTs in post-exposure prophylaxis (PEP-which is close to early treatment) and three in pre-exposure prophylaxis (PrEP-true prevention). Two studies used confirmed or suspected COVID-19 (mainly suspected) as their primary endpoints, and the other four used laboratory-confirmed COVID-19. Dosages differed – notably, the largest PrEP study (>75% of the PrEP data) used a much lower hydroxychloroquine dose, closer to that used in antimalarial chemoprophylaxis rather than the more widely used rheumatoid arthritis doses used in other COVID-19 prophylaxis trials. Another PrEP study reported only a single case of COVID-19; and none of the data in any of the included studies were collected outside of North America or Europe. There were other differences which overall may be summarised as “substantial heterogeneity” between studies. There is certainly not enough evidence to recommend hydroxychloroquine for COVID-19 prophylaxis (there never has been), but is this small and heterogeneous evidence base enough to state conclusively, as the WHO guideline has done, that hydroxychloroquine does not provide a modest but worthwhile benefit? Does it justify the implicit recommendation that ongoing RCTs in the prevention of COVID-19 should stop now?

These six randomised controlled comparisons enrolled 6,059 participants, but they generated few endpoints (suspected or confirmed COVID-19, hospital admission or death). In the three PEP trials there were only 26 confirmed COVID-19 cases in total (15 of 1,197 randomised to hydroxychloroquine, 11 of 687 randomised to placebo). With so few events and considerable heterogeneity in design, the meta-analysis is sensitive to the methods employed. A previous meta-analysis chose to use the appropriately adjusted primary endpoints reported in each hydroxychloroquine prevention study (e.g. one study was a cluster randomised trial so adjustment for cluster was necessary). This estimated a meta-analytic risk ratio of 0.86 (95% confidence interval [C.I.] 0.70 to 1.06) in the direction of benefit from hydroxychloroquine. In comparison, the WHO guideline decided to use laboratory confirmed COVID-19 (asymptomatic and symptomatic) for the primary endpoint in their meta-analysis of virological effect, without intra-study adjustments, resulting in a meta-analytic odds ratio of 1.03 (95% C.I. 0.80 to 1.32). Figure 1 compares the two analyses.

Figure 1. Comparison of forest plots for the effect of hydroxychloroquine in the prevention of COVID-19. The top forest plot (treatment effect summarised as odds-ratios) is reproduced from reference under a CC-BY-NC 4.0 International license. This describes the evidence synthesis quoted in the WHO guidelines. The forest plot used different end-points to the study primary end-points. It shows a summary odds ratio very close to 1 indicating no difference between the hydroxychloroquine and no treatment arms; the bottom forest plot (treatment effects summarised as risk ratios) is reproduced under a CC-BY-NC 4.0 International license with permission from reference (main text). This does use the original study primary end-points adjusted for study design. This result is in the direction of benefit from hydroxychloroquine, although it is not statistically significant. Differences in the estimated effects between the two analyses reflect the differences in endpoint definitions and the use of intra-study adjusted treatment effects. This illustrates the sensitivity of the preventive effect estimates to the choice of end-points and methods of calculation.
The WHO guideline development panel decided that “Mortality would be the outcome most important to individuals, followed by need for hospital admission, laboratory confirmed SARS-CoV-2 infection, and adverse effects leading to discontinuation”\(^1\). The guideline review determined that there was no important difference in mortality, admission to hospital, or laboratory confirmed COVID-19, and that the evidence quality to support these statements was high. The four-star “High GRADE rating” is defined as: “the authors have a lot of confidence that the true effect is similar to the estimated effect”. Yet there were only 13 deaths in total in the six prophylaxis trials, and all 13 were from one cluster-randomised non-blinded PEP trial\(^1\). Five were in subjects allocated hydroxychloroquine (one of whom took no drug) and eight were in subjects allocated to no drug. So, without a single death in the three PrEP RCTs, and a highly unstable odds ratio of 0.67 for a mortality benefit in subjects allocated to hydroxychloroquine versus those who were not in the PEP RCTs (95% CI: 0.22 to 2.05), the WHO panel were able to conclude that this provided “high certainty evidence” that hydroxychloroquine pre-exposure prophylaxis does not reduce COVID-19 mortality\(^1,2\). This is very difficult to understand, although we are told that MAGIC (the Magic Evidence Ecosystem Foundation) provided methodological support for the guidelines. For the “second most important outcome” in the six RCTs there were only 49 hospital admissions in total (20 in the PrEP RCTs; 11 hydroxychloroquine, nine placebo). In the PrEP studies only two admissions were for COVID-19. These data clearly do not exclude modest but clinically significant differences in the two “most important” outcomes, and most certainly do not equate to “high certainty evidence”.

These chemoprevention evaluations\(^1,2,15\) should be contrasted with the earlier treatment assessments by the WHO guideline group of dexamethasone and hydroxychloroquine in hospitalised COVID-19 patients\(^16,17\) (Figure 2). The evidence that dexamethasone reduces mortality in hospitalised patients with COVID-19 receiving respiratory support was reviewed by the WHO guideline group in September 2020\(^16\). Their judgement was based on the very large platform RCT (RECOVERY), in which there were 980 deaths. The odds ratio for death in dexamethasone recipients receiving respiratory support was 0.82 (95%CI: 0.72 to 0.92)\(^16\). As a result, dexamethasone has since become universally adopted as standard of care for hospitalised patients with COVID-19 who require respiratory support. For hydroxychloroquine, lack of efficacy was concluded from the outcomes of 10,859 mainly hospitalised patients (almost half from the RECOVERY trial) with over 2,000 deaths. The stratified meta-analytic estimate for mortality when combining the RECOVERY\(^4\) and SOLIDARITY\(^8\) trials (which used the same hydroxychloroquine dosage) resulted in a 95% confidence interval for the risk ratio of between 0.98 and 1.21\(^6\). However, both of these results were graded only as “moderate certainty evidence” (defined as: “the true effect is probably close to the estimated effect”) with serious risk of bias (Figure 2)\(^16,17\). So somehow these effect estimates (and thus the certainty of the treatment recommendations) based on thousands of deaths in well conducted RCTs are considered less certain.

<table>
<thead>
<tr>
<th>Treatment &amp; patient group</th>
<th>Endpoint</th>
<th>Underlying data</th>
<th>Evidence appraisal</th>
</tr>
</thead>
</table>
| Dexamethasone for severe COVID-19 (on respiratory support) | Mortality | 1 multicentre randomised open label trial:  
• RECOVERY: 980 deaths/3883  
[OR: 0.82 (0.72-0.94)] | Benefit: Moderate certainty:  
the authors believe that the true effect is probably close to the estimated effect  
Risk of bias: Serious |
| Hydroxychloroquine to treat confirmed COVID-19 | Mortality | 10859 patients from 7 trials, of which 60% are from:  
• RECOVERY: 1211 deaths/4716  
[OR: 1.09 (0.97-1.23)]  
• SOLIDARITY: 188 deaths/1853  
[OR: 1.19 (0.89-1.59)] | No benefit: Moderate certainty:  
the authors believe that the true effect is probably close to the estimated effect  
Risk of bias: Serious |
| Hydroxychloroquine to prevent COVID-19 | Mortality | 1 cluster randomised open label PEP trial. There were no deaths in the PrEP trials  
• Mitjà et al.: 13 deaths/2314 contacts of COVID-19 cases  
[OR: 0.67 (0.22-2.05)] | No benefit: High certainty:  
the authors have a lot of confidence that the true effect is similar to the estimated effect  
Risk of bias: No serious concerns |

Figure 2. Comparison of WHO evidence grading in guidelines\(^16,17\). Upper tier: mortality outcome for dexamethasone in severe COVID-19 (hospitalised and receiving respiratory support); Middle tier: hydroxychloroquine in patients with confirmed COVID-19. This pooled data from hospitalised (87.4%) and outpatient studies (12.6%)\(^14\); Lower tier: hydroxychloroquine for the prevention of COVID-19\(^1,2\).
Toxicity and tolerability are critical considerations for prophylaxis. In justifying their strong negative recommendation, the WHO chemoprevention guideline states that hydroxychloroquine “probably increases the risk of adverse effects leading to discontinuation of the drug (moderate certainty)”\(^1\).\(^2\). Aside from (i) whether it is correct to pool toxicity assessments across different dose regimens, (ii) whether the more subjective measure of discontinuation should be evaluated rather than standardised severity gradings for AEs, and (iii) whether unblinded evidence should be included, there is an important mistake in the calculations. The WHO meta-analysis of AEs leading to study drug discontinuation miscoded the number of AEs in the study by Grau-Pujol et al.\(^1\).\(^2\). There were actually more discontinuations in the placebo group (n=5) than in the hydroxychloroquine group (n=1) (the WHO analysis had these figures mistakenly reversed). Figure 3 shows the incorrect forest plot claiming a significant difference, with a corrected version below. After correction for the miscoded AEs in the Grau-Pujol study, there is no longer a significant difference and the 95% confidence interval for the odds ratio now ranges from 0.83 to 3.29. This emphasises the danger of issuing “strong” recommendations on the basis of unverified and limited data.

By issuing a strong judgement on the basis of scanty evidence (some of which is incorrect), and recommending that trials should stop, the WHO committee has decided that if efficacy were to be shown by continuing current trials (a 30% reduction in the risk of COVID-19 is compatible with the results from these trials\(^1\),\(^2\)), then hydroxychloroquine should still not be used. What are the implications of this judgement? Any recommendation from the WHO must be taken very seriously. Such recommendations are very influential, and these may well stop all ongoing studies. Once closed, clinical trials will not reopen. If followed, this recommendation could prevent us ever knowing the truth.

It is reasonable to conclude already that hydroxychloroquine does not provide high prevention or early treatment efficacies. Vaccines are rightly the priority. The COVID-19 vaccines give high levels of protective efficacy, albeit of limited duration, and must be deployed as widely as possible. For therapeutics the preliminary evidence to date suggests that monoclonal antibodies are more effective than small molecule repurposed antiviral candidates\(^3\). But limited resource settings are unlikely to have high vaccine coverage for many months or even years, and global access to expensive antibody therapies is very uncertain. An inexpensive, well established, widely available and relatively well tolerated drug providing moderate preventive efficacy would still be valuable particularly in situations where there are outbreaks of vaccine escape mutations. Hydroxychloroquine is still being recommended by several countries so solid and convincing evidence of benefit or lack of benefit is still needed. The guideline group recommended that “resources should rather be oriented to evaluate other more promising drugs to prevent COVID-19”. Recently registered trials are not proposing to evaluate hydroxychloroquine, so the main purpose of this recommendation seems to be to stop ongoing trials. We appreciate the urgency of COVID-19 and the need to accelerate research and share research outputs so that responsible guidance can be provided rapidly. The risks and the benefits of hydroxychloroquine and chloroquine COVID-19 prophylaxis have not yet been characterised adequately. The WHO guideline is based on inadequate evidence and erroneous judgements. Randomised controlled trials should continue. Guidelines on the prevention...
References

The authors have put forth a cogent argument that the WHO guideline lacked sufficiently strong evidence to support the positions that it had taken. They have, however, also acknowledged that hydroxychloroquine (HCQ) does not provide high prevention or post-exposure efficacy. Based on the trials published/ongoing, it might be possible that HCQ might yet be found to provide "moderate efficacy" in prophylaxis against COVID-19. It is equally if not more likely that the results would demonstrate lack of significant efficacy, while subjecting the participants to a small but definite risk of harm.

I think it might be helpful if the authors clarified their position at their end. Should all ongoing HCQ prophylaxis trials be continued, or should there be some attempt at coordination so that only one or a minimum number of definitive trials be run? Taken to the extreme, this could mean that trials could continue to be run for different dosages of HCQ, or in combination with other agents. The issue of focusing resources is an important one, particularly during this ongoing pandemic.

Finally, I could not find in the letter any statement on whether some or all authors are involved in HCQ prophylaxis trials. It might be helpful for purposes of transparency to state this.

Is the rationale for the Open Letter provided in sufficient detail?
Partly

Does the article adequately reference differing views and opinions?
Yes

Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Yes
Is the Open Letter written in accessible language?
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Infectious diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 27 Sep 2021

**William Schilling**, Nuffield Department of Medicine, University of Oxford, Oxford, UK

We thank the referee for their helpful comments.

In response to Reviewer 2:
We accept that there is equipoise (i.e. that the WHO conclusions are premature and unjustified) and therefore that trials should continue and should not be stopped. Large and definitive randomized controlled trials are the best way to resolve the uncertainty. To clarify our position as requested we have added these sentences at the end of the paper.
“The risks and the benefits of hydroxychloroquine and chloroquine COVID-19 prophylaxis have not yet been characterised adequately. The WHO guideline is based on inadequate evidence and errors. Randomised controlled trials should continue."
“The authors are investigators on: “Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)the COPCOV study”. This is stated under “competing interests”.

**Competing Interests:** WS, who wrote this response, declares no competing interests.

Reviewer Report 24 May 2021

https://doi.org/10.21956/wellcomeopenres.18462.r43685

© 2021 Tambyah P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paul Anantharajah Tambyah
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Page 9 of 12
This is a very important open letter that raises significant questions about a "strong" recommendation from the WHO living guideline. The points are made well but there are some areas which could be clearer.

1. The analogy with a legal judgement is good but there are differences. Most decisions in clinical medicine are not as clear cut as "guilty or not guilty" and they offer a balance of risks vs benefits. This is important especially in this case as the risks have been significantly distorted by a retracted paper which had a material effect on recruitment on some of the larger studies cited.

2. In a similar vein, it would have been good to have a couple of lines at least about the Surgisphere fiasco and its impact on recruitment for major ongoing clinical trials at the time. While the fiasco is still fresh in the minds of many of us now, it will be long forgotten before some time and it would be good to have a critical record of the impact of the rush to publication by some of the major medical journals who may not have exercised the same degree of due diligence that would have been exercised pre-pandemic.

3. While the forest plots are interesting especially to statisticians, for most clinicians, they are not that easy to understand and by separating them, it is easy to misunderstand whether the authors of this open letter are endorsing the views of the WHO guideline authors.

4. It would be good to have a table listing the trials that were included in the WHO guideline and to list the strengths and weaknesses of each study (e.g. sample size, end point, etc.).

5. It would also be interesting to point out the direction and magnitude of the impact of HCQ which seems to be quite consistent in the studies. Small but not negative and similarly for the adverse effect profile.

6. It would also be good to add in the studies which are still ongoing or have been published recently - perhaps as a supplementary appendix if this is done with this journal.

Is the rationale for the Open Letter provided in sufficient detail?
Yes

Does the article adequately reference differing views and opinions?
Partly

Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Yes

Is the Open Letter written in accessible language?
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?
Partly
**Competing Interests:** I have no direct competing interests but I have met and interacted with Prof Sir Nicholas White about our own prophylaxis study as well as numerous other areas in infectious diseases over the last 20 years

**Reviewer Expertise:** Clinical trials, emerging infectious diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 27 Sep 2021

William Schilling, Nuffield Department of Medicine, University of Oxford, Oxford, UK

We thank the referee for their constructive comments

In response to Professor Paul Tambyah

1. The analogy with a legal judgement is good but there are differences. Most decisions in clinical medicine are not as clear cut as “guilty or not guilty” and they offer a balance of risks vs benefits. This is important especially in this case as the risks have been significantly distorted by a retracted paper which had a material effect on recruitment on some of the larger studies cited. We do agree

2. In a similar vein, it would have been good to have a couple of lines at least about the Surgisphere fiasco and its impact on recruitment for major ongoing clinical trials at the time. While the fiasco is still fresh in the minds of many of us now, it will be long forgotten before some time and it would be good to have a critical record of the impact of the rush to publication by some of the major medical journals who may not have exercised the same degree of due diligence that would have been exercised pre-pandemic. We have expanded our description as follows:

Unfortunately, in addition to extreme politicisation and extensive speculation, perceptions of risk from hydroxychloroquine were distorted, and ongoing trials were badly damaged by the Surgisphere® fiasco in May 2020 (7). A very large multinational study, led by eminent cardiologists and published in The Lancet, claimed to show that hydroxychloroquine increased the risk of lethal ventricular arrhythmias. Some regulatory authorities stopped ongoing trials immediately, but it rapidly became apparent that the Surgisphere® data, upon which the study was based, contained implausible results, could not be accessed, and were likely fabricated. Although this paper, and another from the same team published earlier in the New England Journal of Medicine [NW1], were swiftly retracted (7) the regulatory authorities were slow to reverse their positions, opinion swung against the drugs despite the false report, and lasting damage was done.

3. While the forest plots are interesting especially to statisticians, for most clinicians, they are not that easy to understand and by separating them, it is easy to misunderstand whether the authors of this open letter are endorsing the views of the WHO guideline authors. We have clarified our interpretation in the legend to Figure 1 as follows:

*b*Figure 1: Comparison of forest plots for the effect of hydroxychloroquine in the prevention of COVID-19. The top forest plot (treatment effect summarised as odds-ratios) is reproduced from...*
the WHO guidelines and uses different end-points to the study primary end-points (11) (supplementary materials). It shows a summary odds ratio very close to 1 indicating no difference between the hydroxychloroquine and no treatment arms; the bottom forest plot (treatment effects summarised as risk ratios) is reproduced with permission from (10) (main text). It uses the original study primary end-points adjusted for study design. In contrast this result is in the direction of benefit from hydroxychloroquine although it is not statistically significant. Differences in the estimated effects between the two analyses reflect the differences between endpoint definitions and the use of intra-study adjusted treatment effects. This illustrates the sensitivity of the preventive effect estimates to the choice of end-points and methods of calculation.

4. It would be good to have a table listing the trials that were included in the WHO guideline and to list the strengths and weaknesses of each study (e.g. sample size, end point, etc.). Thank you, the strengths and weakness of the six studies which comprise the WHO guideline have not been summarised in this paper, although the details of these papers have been summarised in the Bartoszko et al. living systematic review and meta-analysis referenced in this paper.

5. It would also be interesting to point out the direction and magnitude of the impact of HCQ which seems to be quite consistent in the studies. Small but not negative and similarly for the adverse effect profile.

Thank you- we have updated accordingly.

6. It would also be good to add in the studies which are still ongoing or have been published recently - perhaps as a supplementary appendix if this is done with this journal. We have added an update section as an appendix at the end of the paper to address specifically these important points.


**Competing Interests:** WS, who wrote these comments declares no competing interests.